Objective:To evaluate efficacy of Agomelatine versus Duloxetine on depressive disorder. Methods:108 patients meeting ICD-10 criteria of depressive disorders were randomized into study group (n=54, treated with Agomelatine for 8 weeks) and control group (n=54, treated with Duloxetine for 8 weeks). All patients were assessed with Hamilton depression scale (HAMD) and treatment emergent symptom scale (TESS) at baseline and the end of the 2nd, 4th, 8th week of the treatment to evaluate the efficacy and safety, respectively. Results:There was no significant difference in response rate at the end of the 8th week between study group and control group (72. 2% vs 63. 0%%, P>0. 05). The scores of HAMD in both group decreased significantly at the end of the 2nd, 4th, and 8th week when compared with the baseline (P<0. 01), but there was also no significant difference between the two groups (P>0.05). There were no significant differences in frequency and score of side effects between study group and control group (P>0. 05). Conclusions:Compared with Duloxetine, Agomelatine has similar therapeutic effects in the treatment of patients with depres-sive disorders.%目的：：探讨阿戈美拉汀与度洛西汀治疗抑郁症患者的疗效分析。方法：对符合ICD-10诊断的108例抑郁症患者按随机数字表法分为研究组和对照组，每组各54例。研究组患者单一使用阿戈美拉汀治疗；对照组患者单一使用度洛西汀治疗。在基线、2周末、4周末、8周末，采用汉密顿抑郁量表( HAMD)和不良反应症状量表( TESS)对两组患者进行疗效和安全性评估。结果：在治疗后8周末，研究组和对照组患者的临床治疗有效率分别为72.2%和63.0%，两组患者比较，差异无统计学意义(P>0.05)。治疗后第2、4、8周末，两组患者的HAMD总分与治疗前比较均显著下降(P<0.01)，两组间比较差异无统计学意义(P>0.05)。研究组患者的不良反应与对照组比较，得分及分布差异均无统计学意义(P>0.05)。结论：阿戈美拉汀治疗抑郁症患者的疗效与度洛西汀相当。
展开▼
